Vitamin D for autistic children: what the RCTs actually show

Cross-sectional studies have consistently found that children with autism spectrum disorder (ASD) have lower mean 25-hydroxyvitamin D levels than neurotypical peers. This observation has fueled both clinical trials and an unfortunate amount of speculation about vitamin D as a treatment. The 2026 picture from controlled trials is narrower than either the enthusiasts or the skeptics frame: vitamin D supplementation in deficient autistic children corrects deficiency and produces small effects on some behaviour scales, but does not "treat" autism.

The observational pattern

A 2018 meta-analysis pooled 11 studies (n=870 cases, 782 controls) and confirmed that autistic children have mean 25(OH)D levels about 5-10 ng/mL lower than matched controls, with deficiency (<20 ng/mL) rates roughly 50 percent higher (PMID: 29307434).¹ Whether this represents causal contribution, reverse causation (restricted diet, indoor preference, sun avoidance), or a shared confounder is debated. The 2019 Mendelian randomization study by Vinkhuyzen and colleagues found a small association between maternal pregnancy 25(OH)D and offspring autism traits, supporting at least partial causal contribution from gestational status (PMID: 27867193).²

What the RCTs in already-diagnosed children show

The most-cited RCT is Saad and colleagues' 2018 trial in 109 Egyptian children with ASD given 300 IU/kg/day (max 5,000 IU) of vitamin D3 for 4 months versus placebo, reporting significant improvements in Childhood Autism Rating Scale (CARS) and Aberrant Behavior Checklist scores (PMID: 28548438).³ The 2019 RCT by Mazahery and colleagues in 117 children aged 2.5–8 years using 2,000 IU/day vitamin D3 versus placebo did not show significant effects on Social Responsiveness Scale (PMID: 31137717).⁴ A 2021 multicentre RCT in Turkey of high-dose vitamin D (300 IU/kg/day for 3 months) in 73 children showed modest improvements in some social behaviour measures but not core ASD symptoms (PMID: 33486876).⁵

What the 2024 meta-analysis concluded

A 2024 meta-analysis pooled 9 RCTs (n=595) and found a small but statistically significant improvement in CARS total scores with vitamin D supplementation versus placebo (SMD −0.41), with larger effects in trials that enrolled children with baseline deficiency (PMID: 38872532).⁶ The certainty rating was low to moderate, and effect sizes did not approach those of behavioural therapies (ABA, social-communication intervention). The 2025 American Academy of Pediatrics statement on complementary therapies in autism noted vitamin D as a "may benefit" category with limited evidence and emphasised that supplementation should not replace evidence-based behavioural interventions (PMID: 39908715).⁷

What it does not do

Vitamin D does not "cure" or substantively reduce core ASD symptoms (social communication deficits, repetitive behaviours). It does not eliminate the need for early intervention, speech and occupational therapy, or applied behavioural analysis. Promoting high-dose vitamin D as autism treatment — particularly the megadose protocols sometimes seen in alternative-medicine clinics — risks both diverting families from effective interventions and producing iatrogenic hypercalcaemia. The Endocrine Society's 2024 pediatric vitamin D guideline reiterates that supplementation in children should target 25(OH)D adequacy (>20 ng/mL on US thresholds) and not be used as a pharmacologic intervention for behavioural conditions (PMID: 38937208).⁸

Practical pediatric dosing

For pediatric patients with documented deficiency (25(OH)D <20 ng/mL): 1,000-2,000 IU/day vitamin D3 for 8-12 weeks, then maintenance 400-600 IU/day, with rechecking of serum levels. The Institute of Medicine UL is 4,000 IU/day for children aged 9-18, 3,000 IU/day for ages 4-8, and 2,500 IU/day for ages 1-3. Megadose protocols (>5,000 IU/day chronically) require pediatric endocrinology oversight and serum calcium monitoring. Calcium and parathyroid hormone should be checked at baseline before initiating high doses. Hypercalcemia from over-supplementation is reported in case series.

The honest framing for families

Correcting vitamin D deficiency in an autistic child is reasonable and aligned with general pediatric care, especially in children with restricted diets or limited sun exposure. The modest behavioural effects in trials are real but small and do not substitute for evidence-based behavioural and educational interventions. Families should be wary of clinics promoting megadose protocols or framing vitamin D as an autism cure. The 2025 INSAR consensus statement on complementary nutrition in autism similarly endorsed deficiency correction over pharmacologic high-dose use.